Untiet Sarah, Schmidt Nicole, Low Nicola, Petignat Patrick
Hôpitaux Universitaires de Genève, Genf.
Ther Umsch. 2013 Apr;70(4):223-30. doi: 10.1024/0040-5930/a000393.
At the beginning of the 20th Century, cervical cancer was the leading cause of death from cancer in women. A marked decline in cervical cancer has been observed since the 1960s, in parallel with the introduction of the Papanicolau (Pap) test as a cytological screening method. Today, Pap smear screening is still the most widely used tool for cervical cancer prevention. Testing for human papillomavirus (HPV) in cervical specimens or a combination of Pap and HPV testing are also now available. In this article we compare current guidelines for cervical cancer screening in Switzerland with those in other European countries. In view of the opportunities offered by HPV testing and, since 2008, HPV vaccination, current guidelines for cervical cancer screening should be updated. Both the choice of screening tests and general organization of cervical cancer screening should be reviewed.
在20世纪初，宫颈癌是女性癌症死亡的主要原因。自20世纪60年代以来，随着作为一种细胞学筛查方法的帕潘icolaou（巴氏）试验的引入，宫颈癌发病率显著下降。如今，巴氏涂片筛查仍然是预防宫颈癌最广泛使用的工具。目前也可以对宫颈标本进行人乳头瘤病毒（HPV）检测，或采用巴氏和HPV联合检测。在本文中，我们将瑞士目前的宫颈癌筛查指南与其他欧洲国家的指南进行比较。鉴于HPV检测以及自2008年以来HPV疫苗接种所带来的机遇，目前的宫颈癌筛查指南应予以更新。筛查检测的选择和宫颈癌筛查的总体组织都应重新审视。
